Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- Check3 days agoChange DetectedThe revision label updated from v3.0.1 to v3.0.2, indicating a minor release. The Back to Top element was removed, with no other substantive content changes evident.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of numerous location entries across various countries and the removal of several previous location listings. Additionally, there are updates to MedlinePlus related topics, specifically the inclusion of 'Drug Safety' and 'Substandard Drugs'.SummaryDifference13%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.